Literature DB >> 10699529

Tibiofibular syndesmosis and ossification. Case report: sequelae of ankle sprain in an adolescent football player.

M A Kennedy1, A E Sama, M Sigman.   

Abstract

Heterotopic ossification development within the interosseous membrane of the ankle is an uncommon occurrence after routine ankle sprains. We present a case of a high school football player who sustained a syndesmosis ankle sprain. After 4 weeks, he continued to have pain, swelling, and range of motion restriction despite being treated with cryotherapy, NSAIDs, supportive taping, and progressive rehabilitation. The radiographs revealed a heterotopic ossification within the interosseous membrane of the distal extremity. The patient was initially treated conservatively and went on to have surgical excision with an excellent result. Symptomatic patients will require definitive surgery even without frank synostosis.

Entities:  

Mesh:

Year:  2000        PMID: 10699529     DOI: 10.1016/s0736-4679(99)00201-2

Source DB:  PubMed          Journal:  J Emerg Med        ISSN: 0736-4679            Impact factor:   1.484


  4 in total

1.  Lateral and syndesmotic ankle sprain injuries: a narrative literature review.

Authors:  Joshua C Dubin; Doug Comeau; Rebecca I McClelland; Rachel A Dubin; Ernest Ferrel
Journal:  J Chiropr Med       Date:  2011-07-23

2.  Diagnostic problem solving in male collegiate athletic trainers.

Authors:  Fredrick A Gardin; James M Mensch
Journal:  J Athl Train       Date:  2014-06-27       Impact factor: 2.860

3.  Ossification of the Interosseous Membrane of the Leg in a Football Player: Case Report and Review of the Literature.

Authors:  Roberto Postacchini; Stefano Carbone; Marco Mastantuono; Carlo Della Rocca; Franco Postacchini
Journal:  Case Rep Orthop       Date:  2016-01-06

4.  Correlation factors for distal syndesmosis ossification following internal fixation of ankle fracture.

Authors:  Lu Bai; Wen Zhou; Wentao Zhang; Jianxin Liu; Honglei Zhang
Journal:  Sci Rep       Date:  2018-08-23       Impact factor: 4.379

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.